Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -9.77% is 67% above its 5-year average of -29.37%, near the high end of its 5-year range (-276.47%–78.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 1056.10% below its 12-month average of -0.85%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -9.77%.
RETURN ON INVESTED CAPITAL (ROIC)
-9.77%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-0.85%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-20.03%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-29.37%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-43.77%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-31.84%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
-29.27%
CURRENT VS TTM AVG
-1056.10%
CURRENT VS 3Y AVG
+51.22%
CURRENT VS 5Y AVG
+66.73%
CURRENT VS 10Y AVG
+77.67%
CURRENT VS 15Y AVG
+69.31%
CURRENT VS 20Y AVG
+66.61%
SECTOR MEDIAN · HEALTHCARE
-34.10%
median of 677 covered companies
CURRENT VS SECTOR MEDIAN
+71.34%
vs the sector median at left
Gyre Therapeutics, Inc.
Market Cap
$796.09M
Return on Invested Capital (ROIC)
-9.77%
TTM Avg
-0.85%
3Y Avg
-20.03%
5Y Avg
-29.37%
Market Cap
$796.60M
Return on Invested Capital (ROIC)
-0.26%
TTM Avg
4.90%
3Y Avg
-0.53%
5Y Avg
1.15%
Market Cap
$804.20M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$805.59M
Return on Invested Capital (ROIC)
9.20%
TTM Avg
13.08%
3Y Avg
19.17%
5Y Avg
23.78%
Market Cap
$789.71M
Return on Invested Capital (ROIC)
-8.34%
TTM Avg
-22.82%
3Y Avg
-51.67%
5Y Avg
-50.32%
Market Cap
$785.87M
Return on Invested Capital (ROIC)
-23.16%
TTM Avg
-53.28%
3Y Avg
-63.06%
5Y Avg
-59.41%
Market Cap
$817.22M
Return on Invested Capital (ROIC)
-7.99%
TTM Avg
-8.85%
3Y Avg
-21.37%
5Y Avg
-42.56%
Market Cap
$774.92M
Return on Invested Capital (ROIC)
-42.83%
TTM Avg
-51.53%
3Y Avg
-51.53%
5Y Avg
-51.53%
Market Cap
$826.20M
Return on Invested Capital (ROIC)
-23.80%
TTM Avg
-58.06%
3Y Avg
-39.20%
5Y Avg
-32.57%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | $796.09M | -9.77% | -0.85% | -20.03% | -29.37% |
| AdaptHealth Corp. (AHCO)vs › | $796.60M | -0.26% | 4.90% | -0.53% | 1.15% |
| Apnimed, Inc. (APMD)vs › | $804.20M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 9.20% | 13.08% | 19.17% | 23.78% |
| Geron Corporation (GERN)vs › | $789.71M | -8.34% | -22.82% | -51.67% | -50.32% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $785.87M | -23.16% | -53.28% | -63.06% | -59.41% |
| Ardelyx, Inc. (ARDX)vs › | $817.22M | -7.99% | -8.85% | -21.37% | -42.56% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.92M | -42.83% | -51.53% | -51.53% | -51.53% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $826.20M | -23.80% | -58.06% | -39.20% | -32.57% |
| Mesa Laboratories, Inc. (MLAB)vs › | $773.58M | 3.29% | 2.60% | -15.46% | -9.88% |
ROIC
-9.8%
ROE
-13.3%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -9.77% |
| 2026-03-31 | -3.20% |
| 2025-12-31 | 2.73% |
| 2025-09-30 | 3.71% |
| 2025-06-30 | 2.30% |
| 2025-03-31 | 7.16% |
| 2024-12-31 | 11.81% |
| 2024-09-30 | -68.82% |
| 2024-06-30 | -64.10% |
| 2024-03-31 | -64.20% |
| 2023-12-31 | -69.67% |
| 2023-06-30 | 11.64% |
| 2023-03-31 | 78.00% |
| 2022-12-31 | -14.17% |
| 2022-09-30 | -45.50% |
| 2022-06-30 | -81.96% |
| 2022-03-31 | -276.47% |
| 2021-12-31 | -202.18% |
| 2021-09-30 | -136.90% |
| 2021-06-30 | -87.80% |
| 2021-03-31 | -70.79% |
| 2020-12-31 | -73.82% |
| 2020-09-30 | -54.99% |
| 2020-06-30 | -44.89% |
| 2020-03-31 | -47.00% |
| 2019-12-31 | -81.66% |
| 2019-09-30 | -66.08% |
| 2019-06-30 | -52.69% |
| 2019-03-31 | -39.70% |
| 2018-12-31 | -28.16% |
| 2018-09-30 | -21.49% |
| 2018-06-30 | -18.60% |
| 2018-03-31 | -17.02% |
| 2017-12-31 | -60.86% |
| 2017-09-30 | -69.85% |
| 2017-06-30 | -58.28% |
| 2017-03-31 | -75.58% |
| 2016-12-31 | -57.47% |
| 2016-09-30 | -40.34% |
| 2016-06-30 | -33.48% |
| 2016-03-31 | -29.65% |
| 2015-12-31 | -30.21% |
| 2015-09-30 | 3.32% |
| 2015-06-30 | 1.27% |
| 2015-03-31 | -2.50% |
| 2014-12-31 | -6.88% |
| 2014-09-30 | -33.77% |
| 2014-06-30 | -39.46% |
| 2014-03-31 | -40.55% |
| 2013-12-31 | -34.78% |
| 2013-09-30 | -33.88% |
| 2013-06-30 | -28.24% |
| 2013-03-31 | -10.74% |
| 2012-12-31 | -4.54% |
| 2012-09-30 | -1.04% |
| 2012-06-30 | -1.62% |
| 2012-03-31 | -10.91% |
| 2011-12-31 | -5.39% |
| 2011-09-30 | -0.28% |
| 2011-06-30 | 4.48% |
| 2011-03-31 | 10.56% |
| 2010-12-31 | 5.98% |
| 2010-09-30 | -6.60% |
| 2010-06-30 | -6.75% |
| 2010-03-31 | -13.44% |
| 2009-12-31 | -18.36% |
| 2009-09-30 | -27.23% |
| 2008-06-30 | -9584.66% |
| 2008-03-31 | -30713.52% |
| 2007-12-31 | -58129.13% |
| 2007-09-30 | -1150.00% |
| 2005-12-31 | -127.00% |
